Literature DB >> 3040462

Org.2766 protects from cisplatin-induced neurotoxicity in rats.

P de Koning, J P Neijt, F G Jennekens, W H Gispen.   

Abstract

One of the side-effects of the cytotoxic drug, cisplatin, is its neurotoxicity. In rats this neurotoxicity can be measured as a slowing of the H-reflex-related sensory nerve conduction velocity. Concurrent treatment with Org.2766 (an ACTH4-9 analog) prevents this neurotoxic side effect while leaving the antitumor activity of cisplatin unaffected.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3040462     DOI： 10.1016/0014-4886(87)90132-4

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  11 in total

Review 1.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

2.  In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4-9) analogue Org 2766.

Authors:  B Kiburg; C Moorer-van Delft; J J Heimans; P C Huijgens; H H Boer
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

3.  Application of a neuroprotective ACTH(4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs.

Authors:  F P Hamers; S F Klis; W H Gispen; G F Smoorenburg
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

Review 4.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

5.  ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.

Authors:  B Bravenboer; A C Kappelle; T van Buren; D W Erkelens; W H Gispen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Effects of cisplatin and ORG.2766 in chick embryonic brain cell cultures.

Authors:  A Bruinink; F Birchler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

7.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

Review 8.  Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy.

Authors:  Jordi Bruna; Paola Alberti; Aina Calls-Cobos; Martial Caillaud; M Imad Damaj; Xavier Navarro
Journal:  Exp Neurol       Date:  2019-12-15       Impact factor: 5.330

9.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.

Authors:  G Cavaletti; G Tredici; P Marmiroli; M G Petruccioli; I Barajon; D Fabbrica
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

10.  Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.

Authors:  B Kiburg; A A van de Loosdrecht; K M Schweitzer; G J Ossenkoppele; L J Müller; J J Heimans; P C Huijgens
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.